This invention describes 11.beta.-aryl-substituted 14,17-ethanoestratrienes of general formula (I). The new compounds are selective estrogens whose action occurs in a tissue-selective manner. The estrogenic action occurs in particular on bone, in the cardiovascular system and in the CNS (central nervous system). Only a slight estrogenic action or no estrogenic action occurs in the uterus and in the liver, however. The compounds are suitable for the production of pharmaceutical agents for use in ...

The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

The invention relates to a steroid compound having the formula (I) ##STR1## comprising a ring E, said ring sharing carbon atoms at position 16 and 17 with the five-membered ring D and being .alpha. with respect to said D-ring. In addition, the carbon atom at position 17 is substituted with an oxygen atom-comprising group through a CO bond. The invention also relates to a pharmaceutical composition comprising said steroid compound. The steroid compounds of the present invention are very suitable ...

Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependent disorders. Preferred compounds have a 1,3,5(10)-estratriene nucleus, and are substituted at the C-17 or C-11 position with a molecular moiety which renders the compounds effective to competitively block the binding of estrogen to its receptor. Particularly preferred compounds are 17-desoxy-1,3,5(10)-estratrienes. Therapeutic methods and pharmaceutical compositions are pr...

Novel analogs of 1.alpha.,25-dihydroxyvitamin D.sub.3 which are selective agonists for the genomic responses or agonists or antagonists for the rapid cellular responses in a wide array of diseases in which 1.alpha.,25-dihydroxyvitamin D.sub.3 or its prodrugs are involved. Novel analogs have general formulae represented by compounds of groups I-V. A method for treatment and prevention of diseases connected with the endocrine system.

Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone, useful as a diuretic, and other compounds of Formula I ##STR1## wherein the variables are as defined by the specification.

The present invention discloses compounds which are cationic cholesteryl derivatives having a nitrogen-containing ring structure as their polar head group. These compounds are useful for delivering biologically active substances to cells and for transfecting nucleic acids into cells.

Steroid derivatives useful as intermediates for producing vitamin D derivates as well as processes for producing the steroid derivatives are provided. The steroid derivatives include halide compounds represented by the following formulae: ##STR1## wherein X, R.sup.1 and R.sup.2 are as defined by the specification.

The invention relates to a process for the preparation of M[Rf.sup.1 OSO.sub.2 NSO.sub.2 ORf.sup.2 ].sub.n wherein Rf.sup.1 and Rf.sup.2 are as define any the specification by reacting bis(chlorosulfonyl)amine with a fluoroalcohol represented Rf.sup.3 OH wherein Rf.sup.3 represents the same of different group which is identical with Rf.sup.1 and Rf.sup.2.

Methods, compositions, and compounds for modulating the GABA.sub.A receptor-chloride ionophore complex to alleviate stress, anxiety, seizures, mood disorders, PMS and PND and to induce anesthesia.